drugset / Trial / NCT00479505

Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder

NCT00479505

Phase 2 Completed 275 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a 12 week study in which different doses of UK-369,003 will be administered to patients with a diagnosis of overactive bladder. Patients will complete a series of questionnaires before treatment, during treatment and after treatment, to assess whether UK-369,003 has improved their symptoms of overactive bladder and erectile function.

Timeline

Start
2007-06
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject GISADENAFIL Small molecule 10 mg
Subject GISADENAFIL Small molecule 25 mg
Subject GISADENAFIL Small molecule 50 mg
Subject GISADENAFIL Small molecule 100 mg

Indications